A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing ... a first for an anti-CD20 [relapsing] MS medicine.” According to the Company, detailed results from the ...

Development of rituximab for induction therapy of lupus nephritis and ... which will evaluate two doses of the humanized anti-CD20 antibody ocrelizumab in combination with steroids ...

“While the early acute adverse events in the course of anti-CD20 therapy appear to be a consequence of cytokine release in the course of B cell depletion, later adverse events might be partly ...

According to Novartis, Kesimpta is the first targeted B cell therapy for RMS that ... will still trail Roche's first-to-market anti-CD20 drug Ocrevus (ocrelizumab), even though that drug needs ...

Higher doses of the company’s intravenously delivered multiple sclerosis drug failed to show additional benefit in slowing ...

The global central nervous system (CNS) market is projected grow to over $80 billion in sales in 2025 for the first time ...

a first for an anti-CD20 RMS medicine." Since its launch, Ocrevus has set a new standard of care in MS and is the most prescribed disease modifying therapy in the United States with more than ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MUSETTE trial ...